학술논문
A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemic Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML)
Document Type
Abstract
Author
Lanieri, Leanne ; Lamothe, Tahirih L ; Miske, Oliver ; McDonough, Sean M ; Sarma, Ganapathy N ; Bhattarai, Prashant ; Latimer, Kellie ; Dushime, Junia ; Jain, Nidhi ; Palchaudhuri, Rahul ; Knihtila, Ryan ; Pearse, Bradley R ; Proctor, Jennifer L ; Boitano, Anthony E; Cooke, Michael P; Davis, John C., Jr.
Source
In Blood 5 November 2020 136 Supplement 1:47-48
Subject
Language
ISSN
0006-4971